Ephedra in Texas
This article was originally published in The Tan Sheet
Executive Summary
Thirty-three warning letters have been sent by Texas Department of Public Health to companies failing to comply with rule requiring ephedrine alkaloid-containing supplements bear a warning against sales to individuals under age 18 and include FDA's MedWatch number on labeling for AE reporting. Nine companies have come into compliance, approximately 10 referred to the Texas AG's office, with the rest pending, department says. Officials say they have not noticed an increase in AE reports since the rule became effective Sept. 1 (1"The Tan Sheet" Sept. 10, 2001, In Brief)...
You may also be interested in...
Ephedrine
Texas Dept. of Health's enforcement of ephedrine rule, which requires supplement labeling to carry FDA's MedWatch number and warning against sales to persons 17 or younger, commenced Sept. 1, DoH confirms Sept. 6. "Whether or not enforcement will include detaining mislabeled products will be determined on a case-by-case basis," department says. Similar provisions have been added to California bill making its way through state legislature. SB 397 cleared Senate June 7. Amendments added during Assembly Health Committee review restrict ephedrine sales to people over 18 and require MedWatch number on label. Assembly Appropriations Cmte. slated to review bill week of Sept. 10
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.